Fennec Pharmaceuticals Inc.
corporate_fare Company Profile
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for FENC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-17, rated 8/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for FENC spans 8-K, 10-Q, DEF 14A, 10-K.
Recent high-impact activity:
- PEDMARK Phase 2 STS-J01: 24% Hearing Loss vs 56.4% Benchmark and 95.8% Tumor Response
- PEDMARK Phase 2 Cuts Hearing Loss to 24% vs 56% Benchmark
- Fennec Q2 Sales Jump 78% to $17.1M, Swings to Profit
- Shareholders Approve Equity Plans Authorizing Over 30% Potential Dilution
- Fennec's PEDMARK Shows Positive Clinical Data, Expanded Use Potential at ASCO
Financial Snapshot
Short Interest & Short Volume
2.11 days to coverFINRA reported short interest of 545,039 shares in FENC as of the September 15, 2026 settlement, a 4.7% increase from the prior period — about 2.1 days to cover at its recent average daily volume. On October 2, 2026, 32.9% of FENC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.